A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 May 2016
At a glance
- Drugs Foretinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms IND197
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 07 Feb 2014 Planned End Date changed from 1 Jan 2016 to 1 Sep 2014 as per ClinicalTrials.gov record..
- 18 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.